Gamma Medica installs pre-clinical imaging system for cancer research

Gamma Medica Inc. last week completed installation of its X-SPECT pre-clinical imaging system at Mayo Clinic in Rochester, Minn., for cancer research.

Specifically, X-SPECT will be used in imaging in vivo gene transfer in animal models with different types of cancer using a variety of vectors. Imaging probes also will be used to demonstrate the success of various gene therapies.

X-SPECT is Gamma Medica's second-generation MicroSPECT system, designed for use by medical researchers and drug companies that use in-vivo imaging techniques and molecular markers to speed studies of disease progression and therapy. The X-SPECT system combines the functional nuclear medicine technique - single photon emission computed tomography (SPECT) -- with anatomical imaging provided by x-ray CT.

Gamma Medica says the upgraded system gantry is similar to other clinical systems, but on a smaller scale with higher resolution and features better suited to the in-vivo imaging of mice and other small animals in the laboratory setting.

Gamma Medica, along with its marketing partner Siemens Medical Solutions USA Inc., sells its MicroSPECT products to bio-pharmaceutical companies, research hospitals and universities.

Around the web

The new technology shows early potential to make a significant impact on imaging workflows and patient care. 

Richard Heller III, MD, RSNA board member and senior VP of policy at Radiology Partners, offers an overview of policies in Congress that are directly impacting imaging.
 

The two companies aim to improve patient access to high-quality MRI scans by combining their artificial intelligence capabilities.